Paclitaxel-induced hepatic steatosis in patients with breast cancer
Küçük Resim Yok
Tarih
2019
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Imprimatur Publications
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Purpose: Paclitaxel has been associated with serum aminotransferase elevations, however, paclitaxel induced hepatosteatosis has not been evaluated systematically. This study assessed the rate of paclitaxel-related hepatosteatosis. Methods: Forty one early breast cancer (BC) patients were included the study. Hepatic ultrasonograpy, demographic features and biochemical liver function tests before and after 12 weeks of paclitaxel were assessed. Results: New-onset hepatosteatosis was developed in 26.7% of the patients. Baseline triglyceride>200mg/dL (OR, 11.25; p=0.015), LDH at baseline > 191.48 IU/L (OR, 4.93; p=0.048), and total bilirubin >0.51 mg/dL after paditaxel (OR, 6.17; p=0.042) were found as independent prognostic markers for new-onset hepatosteatosis. Conclusion: Paclitaxel may induce hepatosteatosis in patients with BC.
Açıklama
Anahtar Kelimeler
paclitaxel, hepatosteatosis, breast cancer
Kaynak
Journal of Buon
WoS Q Değeri
Q4
Scopus Q Değeri
Cilt
24
Sayı
6
